RTSL — Rapid Therapeutic Science Laboratories Income Statement
0.000.00%
Last trade - 00:00- $0.10m
- $3.55m
Annual income statement for Rapid Therapeutic Science Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.009 | 0.001 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 0.002 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.52 | 0.168 | 0.442 | 2.17 | 1.26 |
| Operating Profit | -2.52 | -0.168 | -0.433 | -2.17 | -1.26 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.55 | -0.349 | -0.625 | -2.87 | -1.79 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.55 | -0.349 | -0.625 | -2.87 | -1.79 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.55 | -0.349 | -0.625 | -2.87 | -1.79 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.55 | -0.349 | -0.625 | -2.87 | -1.79 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.83 | -7.27 | -0.26 | -0.376 | -0.232 |